Collaboration revenue — Revenue
Regeneron Pharmaceuticals Collaboration revenue — Revenue decreased by 3.6% to $1.90B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.1%, from $1.53B to $1.90B. Over 2 years (FY 2023 to FY 2025), Collaboration revenue — Revenue shows an upward trend with a 15.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful commercialization or milestone achievement within joint ventures, while a decrease may indicate maturing partnerships or shifts in R&D collaboration strategy.
Detailed definition
Collaboration revenue represents income generated through strategic partnerships and joint development agreements with o...
Peer comparison
Common in large-cap biopharma companies that utilize co-development models, such as those seen in partnerships between major pharmaceutical firms and specialized biotech innovators.
regn_segment_collaboration_revenue_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $954.70M | $1.07B | $1.23B | $1.04B | $1.05B | $1.38B | $1.32B | $1.44B | $1.37B | $1.27B | $1.52B | $1.66B | $1.61B | $1.53B | $1.86B | $1.97B | $1.97B | $1.90B |
| QoQ Change | — | +12.5% | +14.8% | -15.3% | +0.7% | +31.2% | -4.5% | +9.2% | -4.7% | -7.5% | +20.3% | +8.9% | -3.2% | -4.7% | +21.5% | +5.8% | +0.1% | -3.6% |
| YoY Change | — | — | — | +9.3% | -2.2% | +11.8% | +26.2% | +36.9% | — | -8.1% | +15.7% | +15.4% | +17.3% | +20.9% | +22.1% | +18.6% | +22.7% | +24.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's collaboration revenue — revenue?
- Regeneron Pharmaceuticals (REGN) reported collaboration revenue — revenue of $1.90B in Q1 2026.
- How has Regeneron Pharmaceuticals's collaboration revenue — revenue changed year-over-year?
- Regeneron Pharmaceuticals's collaboration revenue — revenue increased by 24.1% year-over-year, from $1.53B to $1.90B.
- What is the long-term trend for Regeneron Pharmaceuticals's collaboration revenue — revenue?
- Over 2 years (2023 to 2025), Regeneron Pharmaceuticals's collaboration revenue — revenue has grown at a 15.4% compound annual growth rate (CAGR), from $5.50B to $7.33B.
- What does collaboration revenue — revenue mean?
- Revenue earned from sharing profits and development costs with partner companies on joint drug programs.